Chugai Seiyaku Kabushiki Kaisha

Chugai Suyaku K.k.

Kunihiro Hattori

Tetsuo Kojima

Nozomi Yamaguchi

Masayoshi Oh-Eda

Hideki Adachi

Toru Esaki

Naohiro Yabuta

Takehisa Kitazawa

Taro Miyazaki

Tetsuhiro Soeda

Hiroyuki Saito

Yasushi Shimonaka

Kazutaka Yoshihashi

Toshiro Kozono

Tomokazu Ozaki

Shinya Fujiwara

The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.

Bispecific antibody substituting for functional proteins

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Prevention and treatment of diseases associated with blood coagulation

In the case when there are two objective biological activities, and the aim is to isolate a compound having at least one biological activity, the present inventors developed an assay method wherein a common detection marker is utilized for separately detecting the presence or absence of each of the biological activities. The present inventors discovered that a compound having at least one of two or more distinct biological activities can be efficiently and conveniently detected by simultaneously assaying at least one test sample or more by the above-mentioned method. Furthermore, for a test sample that proved to be positive by the detection method, they found that it is possible to efficiently and conveniently screen for a test sample having an objective specific biological activity by combining with a method wherein an individual activity of a test sample can be detected to specify the biological activity.

Screening methods for biologically active ligands

The compounds of the invention are compounds represented by the following general formula (1):wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, Rrepresents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, Rrepresents one selected from the group consisting of a hydrogen atom and alkyl groups, Wrepresents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, Xrepresents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1;and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

Compounds exhibiting thrombopoietin-like activities

Genes coding for a polypeptide having a human megakaryocyte potentiator activity, recombinant vectors containing said genes, host cells that have been transformed with said recombinant vectors, and a process for producing a polypeptide having a human megakaryocyte potentiator activity by first cultivating said transformed host cells and then isolating the desired polypeptide from the culture.

DNA coding for megakaryocyte potentiator

Megakaryocyte potentiator

Growing community of inventors

Shizuoka, Japan

Kunihiro Hattori